Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Cervical Cancer

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 42 articles:
HTML format



Single Articles


    May 2024
  1. AI Y, Zhu X, Zhang Y, Li W, et al
    MRI radiomics nomogram integrating postoperative adjuvant treatments in recurrence risk prediction for patients with early-stage cervical cancer.
    Radiother Oncol. 2024;197:110328.
    PubMed     Abstract available


    March 2024
  2. SKIPAR K, Hompland T, Lund KV, Lindemann K, et al
    Mri-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy.
    Radiother Oncol. 2024 Mar 29:110263. doi: 10.1016/j.radonc.2024.110263.
    PubMed     Abstract available


  3. KUIPERS SC, Godart J, Corbeau A, Breedveld S, et al
    Dosimetric impact of bone marrow sparing for robustly optimized IMPT for locally advanced cervical cancer.
    Radiother Oncol. 2024 Mar 10:110222. doi: 10.1016/j.radonc.2024.110222.
    PubMed     Abstract available


  4. HUI C, Ewongwo A, Mendoza MG, Kozak MM, et al
    Less than whole uterus irradiation for patients with locally advanced cervical cancer.
    Radiother Oncol. 2024 Mar 2:110199. doi: 10.1016/j.radonc.2024.110199.
    PubMed     Abstract available


    November 2023
  5. REIJTENBAGH D, Godart J, Penninkhof J, Quint S, et al
    Nine years of plan of the day for cervical cancer: Plan library remains effective compared to fully online-adaptive techniques.
    Radiother Oncol. 2023;190:110009.
    PubMed     Abstract available


    September 2023
  6. NOUT R, Calaminus G, Planchamp F, Chargari C, et al
    ESTRO/ESGO/SIOPe guidelines for the management of patients with vaginal cancer.
    Radiother Oncol. 2023;186:109662.
    PubMed     Abstract available


    July 2023
  7. CIBULA D, Rosaria Raspollini M, Planchamp F, Centeno C, et al
    ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023.
    Radiother Oncol. 2023;184:109682.
    PubMed     Abstract available


    June 2023
  8. ECKER S, Kirisits C, Schmid M, Knoth J, et al
    EviGUIDE - A tool for evidence-based decision making in image-guided adaptive brachytherapy for cervical cancer.
    Radiother Oncol. 2023 Jun 15:109748. doi: 10.1016/j.radonc.2023.109748.
    PubMed     Abstract available


  9. CHARGARI C, Tanderup K, Planchamp F, Chiva L, et al
    ESGO/ESTRO quality indicators for radiation therapy of cervical cancer.
    Radiother Oncol. 2023;183:109589.
    PubMed     Abstract available


    March 2023
  10. OKAMOTO H, Murakami N, Isohashi F, Kasamatsu T, et al
    Plan quality association between dummy run and individual case review in a prospective multi-institutional clinical trial of postoperative cervical cancer patients treated with intensity-modulated radiotherapy: Japan Clinical Oncology Group study (JCO
    Radiother Oncol. 2023 Mar 17:109630. doi: 10.1016/j.radonc.2023.109630.
    PubMed     Abstract available


    February 2023
  11. ECKER S, Kirisits C, Paul Schmid M, Agatha Catharina De Leeuw A, et al
    Tools for large-scale data analytics of an international multi-center study in radiation oncology for cervical cancer.
    Radiother Oncol. 2023 Feb 8:109524. doi: 10.1016/j.radonc.2023.109524.
    PubMed     Abstract available


    January 2023
  12. REIJTENBAGH DMW, Godart J, de Leeuw AAC, Jurgenliemk-Schulz IM, et al
    Multi-center dosimetric predictions to improve plan quality for brachytherapy for cervical cancer treatment.
    Radiother Oncol. 2023 Jan 31:109518. doi: 10.1016/j.radonc.2023.109518.
    PubMed     Abstract available


  13. SPAMPINATO S, Tanderup K, Lindegaard JC, Schmid MP, et al
    Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors.
    Radiother Oncol. 2023 Jan 28:109501. doi: 10.1016/j.radonc.2023.109501.
    PubMed     Abstract available


    December 2022
  14. SUPRIYA C, Nilesh R, Mayuri C, Sadhana K, et al
    Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES).
    Radiother Oncol. 2022;177:16-20.
    PubMed     Abstract available


    September 2022
  15. SKIPAR K, Hompland T, Vassmo Lund K, Londalen A, et al
    Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer.
    Radiother Oncol. 2022 Sep 13. pii: S0167-8140(22)04266.
    PubMed     Abstract available


    July 2022
  16. DANKULCHAI P, Harn-Utairasmee P, Prasartseree T, Nakkasae P, et al
    Vaginal 11-point and volumetric dose related to late vaginal complications in patients with cervical cancer treated with external beam radiotherapy and image-guided adaptive brachytherapy.
    Radiother Oncol. 2022 Jul 12. pii: S0167-8140(22)04205.
    PubMed     Abstract available


  17. DAVIDE C, Luca R, Benedetta G, Rosa A, et al
    Evaluation of early regression index as response predictor in cervical cancer: a retrospective study on T2 and DWI MR images.
    Radiother Oncol. 2022 Jul 7. pii: S0167-8140(22)04186.
    PubMed     Abstract available


    May 2022
  18. HANDE V, Chopra S, Kalra B, Abdel-Wahab M, et al
    Point-A vs. volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis.
    Radiother Oncol. 2022;170:70-78.
    PubMed     Abstract available


    February 2022
  19. REIJTENBAGH DMW, Godart J, de Leeuw AAC, Seppenwoolde Y, et al
    Multi-center analysis of machine-learning predicted dose parameters in brachytherapy for cervical cancer.
    Radiother Oncol. 2022 Feb 24. pii: S0167-8140(22)00107.
    PubMed     Abstract available


    January 2022
  20. WESTERVELD H, Kirchheiner K, Nout RA, Tanderup K, et al
    Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: an EMBRACE-I sub-study.
    Radiother Oncol. 2022 Jan 18. pii: S0167-8140(21)09082.
    PubMed     Abstract available


    December 2021
  21. MELL LK
    Trials and tribulations of bone marrow sparing radiotherapy for cervical cancer.
    Radiother Oncol. 2021 Dec 9. pii: S0167-8140(21)09021.
    PubMed    


    October 2021
  22. ZHOU P, Zhang Y, Luo S, Zhang S, et al
    Pelvic bone marrow sparing radiotherapy for cervical cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2021 Oct 27. pii: S0167-8140(21)08782.
    PubMed     Abstract available


  23. SRINIVASAN S, Gurram L, Johnny C, Chopra S, et al
    Validation and applicability of para-aortic lymph nodal contouring atlas in cervical cancer.
    Radiother Oncol. 2021 Oct 25. pii: S0167-8140(21)08781.
    PubMed     Abstract available


    September 2021
  24. CORBEAU A, Kuipers SC, de Boer SM, Horeweg N, et al
    Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review.
    Radiother Oncol. 2021 Sep 21. pii: S0167-8140(21)06732.
    PubMed     Abstract available


  25. PETERS M, de Leeuw AAC, Nomden CN, Tanderup K, et al
    Risk factors for nodal failure after radiochemotherapy and image-guided brachytherapy in locally advanced cervical cancer: an EMBRACE analysis.
    Radiother Oncol. 2021 Sep 1. pii: S0167-8140(21)06714.
    PubMed     Abstract available


    May 2021
  26. MAHANTSHETTY U, Poetter R, Beriwal S, Grover S, et al
    IBS-GEC ESTRO-ABS Recommendations for CT Based Contouring in Image Guided Adaptive Brachytherapy for Cervical cancer.
    Radiother Oncol. 2021 May 17. pii: S0167-8140(21)06248.
    PubMed     Abstract available


  27. YUCE SARI S, Yigit E, Gultekin M, Yildiz F, et al
    In regard to Spampinato et al.
    Radiother Oncol. 2021;158:321-322.
    PubMed    


  28. SPAMPINATO S, Fokdal LU, Potter R, Haie-Meder C, et al
    Response to Yuce Sari et al.
    Radiother Oncol. 2021;158:323-324.
    PubMed    


    April 2021
  29. MOHAMMADI R, Shokatian I, Salehi M, Arabi H, et al
    Deep learning-based Auto-segmentation of Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer.
    Radiother Oncol. 2021 Apr 5. pii: S0167-8140(21)06170.
    PubMed     Abstract available


    March 2021
  30. HUMPHREY P, Dures E, Hoskin P, Cramp F, et al
    Brachytherapy for locally advanced cervical cancer: a survey of UK provision of care and support.
    Radiother Oncol. 2021 Mar 16. pii: S0167-8140(21)06133.
    PubMed     Abstract available


    February 2021
  31. SPAMPINATO S, Fokdal LU, Potter R, Haie-Meder C, et al
    Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: an EMBRACE analysis.
    Radiother Oncol. 2021 Feb 2. pii: S0167-8140(21)00020.
    PubMed     Abstract available


    January 2021
  32. PETRIC P, Lindegaard JC, Sturdza A, Fokdal L, et al
    Results of Image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study.
    Radiother Oncol. 2021 Jan 18. pii: S0167-8140(21)00005.
    PubMed     Abstract available


    October 2020
  33. CHOPRA S, Mangaj A, Sharma A, Tee Tan L, et al
    Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network.
    Radiother Oncol. 2020 Oct 31. pii: S0167-8140(20)30884.
    PubMed     Abstract available


  34. SPAMPINATO S, Fokdal LU, Potter R, Haie-Meder C, et al
    Importance of the ICRU Bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: an EMBRACE analysis.
    Radiother Oncol. 2020 Oct 13. pii: S0167-8140(20)30839.
    PubMed     Abstract available


  35. RODRIGUEZ-LOPEZ JL, Ling DC, Keller A, Kim H, et al
    Ureteral Stenosis after 3D MRI-based Brachytherapy for Cervical Cancer - Have We Identified All the Risk Factors?
    Radiother Oncol. 2020 Oct 13. pii: S0167-8140(20)30846.
    PubMed     Abstract available


  36. LIU Z, Liu X, Guan H, Zhen H, et al
    Development and Validation of a Deep Learning Algorithm for Auto-delineation of Clinical Target Volume and Organs at Risk in Cervical Cancer Radiotherapy.
    Radiother Oncol. 2020 Oct 8. pii: S0167-8140(20)30835.
    PubMed     Abstract available


  37. WATANABE Y, Nakamura S, Ichikawa Y, Ii N, et al
    Early Alteration in Apparent Diffusion Coefficient and Tumor Volume in Cervical Cancer Treated with Chemoradiotherapy or Radiotherapy: Incremental Prognostic Value over Pretreatment Assessments.
    Radiother Oncol. 2020 Oct 8. pii: S0167-8140(20)30834.
    PubMed     Abstract available


    June 2020
  38. DUKE SL, Tan LT, Jensen NBK, Rumpold T, et al
    Implementing an online radiotherapy quality assurance programme with supporting continuous medical education - report from the EMBRACE-II evaluation of cervix cancer IMRT contouring.
    Radiother Oncol. 2020;147:22-29.
    PubMed     Abstract available


    April 2020
  39. SPAMPINATO S, Tanderup K, Marinovskij E, Axelsen S, et al
    MRI-based contouring of functional sub-structures of the lower urinary tract in gynaecological radiotherapy.
    Radiother Oncol. 2020;145:117-124.
    PubMed     Abstract available


  40. SCHMID MP, Fokdal L, Westerveld H, Chargari C, et al
    Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer.
    Radiother Oncol. 2020;145:36-44.
    PubMed     Abstract available


    February 2020
  41. SWAMIDAS J, Kirisits C, De Brabandere M, Hellebust TP, et al
    Image registration, contour propagation and dose accumulation of external beam and brachytherapy in gynecological radiotherapy.
    Radiother Oncol. 2020;143:1-11.
    PubMed     Abstract available


  42. TRAVERSO A, Kazmierski M, Welch ML, Weiss J, et al
    Sensitivity of radiomic features to inter-observer variability and image pre-processing in Apparent Diffusion Coefficient (ADC) maps of cervix cancer patients.
    Radiother Oncol. 2020;143:88-94.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.